Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Oct;26(4):557–562. doi: 10.1128/aac.26.4.557

Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice.

L R Crane, D A Milne, J C Sunstrum, A M Lerner
PMCID: PMC179963  PMID: 6083754

Abstract

The effects of double and triple combinations of acyclovir (ACV), adenine arabinoside (ara-A), arabinosyl hypoxanthine, or interferon on herpes simplex virus type 2 in mouse embryo fibroblasts were measured. These in vitro data were compared with results obtained in mice infected intravaginally with herpes simplex virus type 2 and treated intraperitoneally with low- and high-dose combinations of ACV, ara-A, or polyriboinosinic-polyribocytidylic acid(poly-L-lysine)carboxymethylcellulose complex [poly IC(LC)], an interferon inducer. Although all double combinations and one triple combination evoked synergistic reactions in vitro, results did not necessarily predict in vivo observations. In vivo synergy was observed when combinations of ACV and ara-A and low doses of ara-A-ACV-poly IC(LC) were used. However, toxicity was seen with full-dose nucleoside-poly IC(LC) doublets. The full-dose ACV-ara-A combination completely prevented progression beyond vaginitis, with all animals surviving. The ara-A-ACV results observed in mice, together with in vivo data of others, suggest that this combination might prove clinically useful for certain herpes simplex virus type 2 infections.

Full text

PDF
557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRINK J. J., LEPAGE G. A. METABOLISM AND DISTRIBUTION OF 9-BETA-D-ARABINOFURANOSYLADENINE IN MOUSE TISSUES. Cancer Res. 1964 Jul;24:1042–1049. [PubMed] [Google Scholar]
  2. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  3. Biron K. K., Noblin J. E., de Miranda P., Elion G. B. Uptake, distribution, and anabolism of acyclovir in herpes simplex virus-infected mice. Antimicrob Agents Chemother. 1982 Jan;21(1):44–50. doi: 10.1128/aac.21.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  5. Bryson Y. J., Kronenberg L. H. Combined antiviral effects of interferon, adenine, arabinoside, hypoxanthine arabinoside, and adenine arabinoside-5'-monophosphate in human fibroblast cultures. Antimicrob Agents Chemother. 1977 Feb;11(2):299–306. doi: 10.1128/aac.11.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Champney K. J., Lauter C. B., Bailey E. J., Lerner A. M. Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination. J Clin Invest. 1978 Dec;62(6):1142–1153. doi: 10.1172/JCI109233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Corey L., Benedetti J. K., Critchlow C. W., Remington M. R., Winter C. A., Fahnlander A. L., Smith K., Salter D. L., Keeney R. E., Davis L. G. Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. Am J Med. 1982 Jul 20;73(1A):326–334. doi: 10.1016/0002-9343(82)90117-6. [DOI] [PubMed] [Google Scholar]
  8. ELION G. B., SINGER S., HITCHINGS G. H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem. 1954 Jun;208(2):477–488. [PubMed] [Google Scholar]
  9. Finter N. B. Standardization of assay of interferons. Methods Enzymol. 1981;78(Pt A):14–22. doi: 10.1016/0076-6879(81)78092-3. [DOI] [PubMed] [Google Scholar]
  10. Harned C. L., Nerland D. E., Sonnenfeld G. Effects of passive transfer and induction of gamma (type II immune) interferon preparations on the metabolism of diphenylhydantoin by murine cytochrome P-450. J Interferon Res. 1982;2(1):5–10. doi: 10.1089/jir.1982.2.5. [DOI] [PubMed] [Google Scholar]
  11. Hayden F. G., Schlepushkin A. N., Pushkarskaya N. L. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother. 1984 Jan;25(1):53–57. doi: 10.1128/aac.25.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kern E. R., Richards J. T., Glasgow L. A., Overall J. C., Jr, de Miranda P. Optimal treatment of herpes simplex virus encephalitis in mice with oral acyclovir. Am J Med. 1982 Jul 20;73(1A):125–131. doi: 10.1016/0002-9343(82)90077-8. [DOI] [PubMed] [Google Scholar]
  13. Lerner A. M., Bailey E. J. Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine. J Infect Dis. 1976 Oct;134(4):400–404. doi: 10.1093/infdis/134.4.400. [DOI] [PubMed] [Google Scholar]
  14. Levy H. B., Baer G., Baron S., Buckler C. E., Gibbs C. J., Iadarola M. J., London W. T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975 Oct;132(4):434–439. doi: 10.1093/infdis/132.4.434. [DOI] [PubMed] [Google Scholar]
  15. McManus N. H. Microtiter assay for interferon: microspectrophotometric quantitation of cytopathic effect. Appl Environ Microbiol. 1976 Jan;31(1):35–38. doi: 10.1128/aem.31.1.35-38.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mindel A., Adler M. W., Sutherland S., Fiddian A. P. Intravenous acyclovir treatment for primary genital herpes. Lancet. 1982 Mar 27;1(8274):697–700. doi: 10.1016/s0140-6736(82)92618-6. [DOI] [PubMed] [Google Scholar]
  17. Morahan P. S., Breinig M. C., McGeorge M. B. Immune responses to vaginal or systemic infection of BALB/c mice with herpes simplex virus type 2. J Immunol. 1977 Dec;119(6):2030–2036. [PubMed] [Google Scholar]
  18. Morahan P. S., Cline P. F., Breinig M. C., Murray B. K. Effect of pyran on latency after herpes simplex virus infections. Antimicrob Agents Chemother. 1979 Apr;15(4):547–553. doi: 10.1128/aac.15.4.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Olsen G. A., Kern E. R., Glasgow L. A., Overall J. C. Effect of treatment with exogenous interferon, polyinosinic acid-polyctyidylic acid or polyinosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice. Antimicrob Agents Chemother. 1976 Oct;10(4):668–676. doi: 10.1128/aac.10.4.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Olsen G. A., Kern E. R., Overall J. C., Jr Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. J Infect Dis. 1978 Apr;137(4):428–436. doi: 10.1093/infdis/137.4.428. [DOI] [PubMed] [Google Scholar]
  21. Overall J. C., Jr, Kern E. R., Schlitzer R. L., Friedman S. B., Glasgow L. A. Genital herpesvirus hominis infection in mice. I. Development of an experimental model. Infect Immun. 1975 Mar;11(3):476–480. doi: 10.1128/iai.11.3.476-480.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reyes M. P., Lerner A. M. Interferon and neutralizing antibody in sera of exercised mice with coxsackievirus B-3 myocarditis. Proc Soc Exp Biol Med. 1976 Feb;151(2):333–338. doi: 10.3181/00379727-151-39204. [DOI] [PubMed] [Google Scholar]
  23. Sacks S. L., Scullard G. H., Pollard R. B., Gregory P. B., Robinson W. S., Merigan T. C. Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrob Agents Chemother. 1982 Jan;21(1):93–100. doi: 10.1128/aac.21.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schinazi R. F., Peters J., Williams C. C., Chance D., Nahmias A. J. Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother. 1982 Sep;22(3):499–507. doi: 10.1128/aac.22.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stanwick T. L., Schinazi R. F., Campbell D. E., Nahmias A. J. Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1981 Apr;19(4):672–674. doi: 10.1128/aac.19.4.672. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES